National Institutes of Health: Lupus Erythematosus, Systemic trials

The registry lists 49 Lupus Erythematosus, Systemic studies with National Institutes of Health as lead sponsor. 7 are open to participants now and 13 have results posted.

Early Phase 1 1Phase 1 12Phase 2 21Phase 3 3No phase 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pain Phenotyping of Rheumatic Diseases - An Observational StudyNot yet recruitingNCT07829497
• Deciphering the Genetic Architecture of Autoimmune DiseasesRecruitingNCT06948110
• Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus ErythematosusRecruitingNCT06032923Phase 1/2
• Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by QuestionnairesRecruitingNCT05567198
• The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVDRecruitingNCT05440422Phase 2
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingNCT03816345Phase 1
• Study of Systemic Lupus ErythematosusRecruitingNCT00001372
• Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic LupusTerminatedNCT05306873Phase 2Results posted
• COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedNCT05000216Phase 2Results posted
• Genomic Effects of Glucocorticoids in Patients With Systemic Lupus ErythematosusCompletedNCT04233164Early Phase 1Results posted
• Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus ErythematosusCompletedNCT03618056Phase 1Results posted
• Aerobic Exercise in Women With Systemic Lupus ErythematosusTerminatedNCT03186794Not applicableResults posted
• JBT-101 in Systemic Lupus Erythematosus (SLE)CompletedNCT03093402Phase 2Results posted
• Autologous Polyclonal Tregs for LupusTerminatedNCT02428309Phase 1Results posted
• Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)CompletedNCT02338999Phase 1/2Results posted
• Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)TerminatedNCT01946880Phase 2Results posted
• Vitamin D3 Treatment in Pediatric Systemic Lupus ErythematosusTerminatedNCT01709474Phase 2Results posted
• Abatacept and Cyclophosphamide Combination Therapy for Lupus NephritisCompletedNCT00774852Phase 2Results posted
• Vitamin D3 in Systemic Lupus ErythematosusCompletedNCT00710021Phase 2Results posted
• Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus ErythematosusCompletedNCT00076752Phase 2Results posted
• A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or LupusWithdrawnNCT06238531Phase 1
• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus ErythematosusCompletedNCT02535689Phase 1
• Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLEWithdrawnNCT01702038Phase 2
• Insulin Resistance and Atherosclerosis in Women With LupusCompletedNCT00544102
• Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) StudyCompletedNCT00342095
• Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)WithdrawnNCT00230035Phase 2
• Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)CompletedNCT00094380Phase 1/2
• Health Beliefs and Health Behaviors Among Minorities With Rheumatic DiseasesCompletedNCT00069342
• Study of Families With Twins or Siblings Discordant for Rheumatic DisordersCompletedNCT00055055
• Monoclonal Antibody Treatment for Systemic Lupus ErythematosusCompletedNCT00046774Phase 1
• Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus ErythematosusCompletedNCT00042523
• Anti-CD20 in Systemic Lupus ErythematosusCompletedNCT00036491Phase 1/2
• Positron Emission Tomography (PET) to Locate Areas of White Blood Cell ActivityCompletedNCT00029926
• Humanized LL2IGG to Treat Systemic Lupus ErythematosusCompletedNCT00011908Phase 1
• Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus ErythematosusStatus unknownNCT00008749
• Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus NurtureCompletedNCT00006134
• Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus ErythematosusCompletedNCT00006133Not applicable
• High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV CyclophosphamideCompletedNCT00005778Phase 3
• Lupus Cohort--Thrombotic Events and Coronary Artery DiseaseCompletedNCT00005436
• Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus ErythematosusCompletedNCT00004795Phase 2/3
• Study of Individualized Instruction Versus Pamphlet in Systemic Lupus ErythematosusCompletedNCT00004756Not applicable
• Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus ErythematosusCompletedNCT00004665Phase 2
• Epidemiologic Study of Reproductive Outcome in Women With Systemic Lupus ErythematosusCompletedNCT00004663
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus ErythematosusCompletedNCT00004662Phase 3
• Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus ErythematosusCompletedNCT00004643Phase 2
• Ultraviolet Light Therapy for Systemic Lupus ErythematosusStatus unknownNCT00004375Phase 2
• A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus ErythematosusCompletedNCT00001680Phase 2
• Cyclophosphamide and Fludarabine to Treat Lupus NephritisCompletedNCT00001676Phase 1
• Drug Therapy in Lupus NephropathyCompletedNCT00001212Phase 2